Serum Citrate in Diagnosis and Follow-up for Glaucoma

This study is currently recruiting participants.

Verified by University Hospital, Basel, Switzerland, December 2008

First Received: December 5, 2008 No Changes Posted

Sponsors and Collaborators:	University Hospital, Basel, Switzerland Kantonsspital Bruderholz
Information provided by:	University Hospital, Basel, Switzerland
ClinicalTrials.gov Identifier:	NCT00804063

Purpose

Glaucoma might be a mitochondria associated disease. Since citrate is a major component in mitochondrial metabolism its determination in blood might serve as a biomarker.

Condition	Intervention
Glaucoma	Procedure: drawing blood sample

Genetics Home Reference related topics: early-onset glaucoma

MedlinePlus related topics: Glaucoma

Drug Information available for: Citric acid Sodium Citrate

U.S. FDA Resources

Study Type:	Observational
Study Design:	Case Control, Prospective
Official Title:	Serum Citrate in Diagnosis and Follow-up for Glaucoma

Further study details as provided by University Hospital, Basel, Switzerland:

Primary Outcome Measures:

serum citrate level [ Time Frame: 1 ] [ Designated as safety issue: No ]

Secondary Outcome Measures:

urine citrate [ Time Frame: 1 ] [ Designated as safety issue: No ]

Biospecimen Retention: Samples With DNA

Biospecimen Description:

blood, urine, serum

Estimated Enrollment:	30
Study Start Date:	December 2008
Estimated Study Completion Date:	July 2011
Estimated Primary Completion Date:	December 2010 (Final data collection date for primary outcome measure)

Groups/Cohorts	Assigned Interventions
1 glaucoma patients	Procedure: drawing blood sample fasting blood sample
2 non-glaucoma controls	Procedure: drawing blood sample fasting blood sample

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	Yes
Sampling Method:	Non-Probability Sample

Study Population

tertiary university center

Criteria

Inclusion Criteria:

age> 18 years
glaucoma

Exclusion Criteria:

Active ocular inflammation
Ocular Hypertension
Nephropathy
Alcohol-, Drug abuse
Mitochondriopathy

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00804063

Contacts

Contact: David Goldblum, MD	+41 61 2652525	dgoldblum@uhbs.ch
Contact: Stephan Fraenkl, MD	+41 61 2652525	fraenkls@uhbs.ch

Locations

Switzerland, BS
University Hospital Basel	Recruiting
Basel, BS, Switzerland, 4031
Contact: David Goldblum, MD +41 61 2652525 dgoldblum@uhbs.ch
Contact: Stephan Fraenkl, MD +41 61 2652525 fraenkls@uhbs.ch
Principal Investigator: David Goldblum, MD
Sub-Investigator: Graziella Reinhard

Sponsors and Collaborators

University Hospital, Basel, Switzerland

Kantonsspital Bruderholz

Investigators

Principal Investigator:	David Goldblum, MD	University Hospital Basel
Study Chair:	Josef Flammer, MD	University Hospital Basel
Study Director:	Selim Orguel, MD	University Hospital Basel
Principal Investigator:	Stephan Fraenkl, MD	University Hospital Basel

More Information

Additional Information:

Glaucoma Research Group of the University Basel, Department of Ophthalmology This link exits the ClinicalTrials.gov site

No publications provided

Responsible Party:	University Hospital, Basel, Switzerland ( David Goldblum, MD )
Study ID Numbers:	EK 325/08
Study First Received:	December 5, 2008
Last Updated:	December 5, 2008
ClinicalTrials.gov Identifier:	NCT00804063 History of Changes
Health Authority:	Switzerland: Ethikkommission; Switzerland: Laws and standards

Keywords provided by University Hospital, Basel, Switzerland:

glaucoma
citrate

Study placed in the following topic categories:

Glaucoma
Eye Diseases
Citric Acid
Hypertension
Ocular Hypertension

Additional relevant MeSH terms:

Glaucoma
Eye Diseases
Ocular Hypertension

ClinicalTrials.gov processed this record on May 07, 2009